Welcome to the Amprion 2025 landing page. Please review items of interest below or explore the rest of the website.
Amprion is at AAIC 2025, booth 616
Toronto, Canada | July 27-31, 2025
Mixed pathologies are the rule, not the exception.
Scientific Paper
Alzheimer's & Dementia
“ αSyn-SAA are sensitive and specific for ante mortem identification of cortical α-synuclein pathologic change as a primary pathology or as a copathology.”
Aug 2024
Read MoreScientific Paper
Molecular Neurodegeneration
“…our findings suggest that αSyn co-pathology, as detected via CSF-based αSyn SAAs, plays a critical role in accelerating Aβ-induced tau pathophysiology and cognitive decline across the AD spectrum.”
18 Mar 2025
Read MoreScientific Paper
Neurobiology of aging
“These findings suggest that CSF α-synuclein SAA, in combination with APOE ε4 status, could serve as biomarkers for predicting cognitive decline in AD.”
Jun 2025
Read MoreScientific Paper
Alzheimer's & Dementia
“SAA+ individuals had faster cognitive decline than SAA−, notably in mild cognitive impairment, and presented with earlier symptom onset.”
Dec 2024
Read MoreScientific Paper
Alzheimer's & Dementia
“Taken together, the results highlight the notable benefit of measuring AD and Lewy body co-pathologies and show the importance of measuring co-pathologies...”
Nov 2024
Read MoreScientific Paper
Alzheimer's & Dementia
“The [α-syn SAA] demonstrates high diagnostic utility for detecting early-stage synucleinopathies in [CSF], providing a promising biomarker for Alzheimer’s-related neurodegenerative conditions with synuclein co-pathology.”
Nov 2024
Read MoreScientific Paper
Alzheimer's & Dementia
“Lewy body pathology modifies risk factors for cerebral amyloid angiopathy (CAA) when present along with Alzheimer’s disease (AD) neuropathology.”
Apr 2024
Read More
Get in the Know
Bring biological certainty to your diagnosis with Amprion's SAAmplify-ɑSYN test. Order your shipping kits today and help move your patient beyond a probable diagnosis.
